{
    "Trade/Device Name(s)": [
        "ADVIA Centaur EBV-EBNA IgG"
    ],
    "Submitter Information": "Biokit, S.A.",
    "510(k) Number": "K233605",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040120"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "LLM",
        "LSE"
    ],
    "Summary Letter Date": "July 29, 2024",
    "Summary Letter Received Date": "July 29, 2024",
    "Submission Date": "2023-11-09",
    "Regulation Number(s)": [
        "21 CFR 866.3235"
    ],
    "Regulation Name(s)": [
        "Epstein-Barr Virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Epstein-Barr virus nuclear antigen (EBNA)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube",
        "Serum separator tube (SST)"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Automated 2-step sandwich immunoassay",
        "Acridinium ester chemiluminescent technology"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur EBV-EBNA IgG qualitative detection of IgG antibodies to EBV-EBNA in serum and plasma using ADVIA Centaur XP system",
    "Indications for Use Summary": "Qualitative detection of IgG antibodies to Epstein-Barr virus nuclear antigen (EBNA) in pediatric (2\u201321 years) and adult serum and plasma (EDTA and lithium heparin) as an aid in diagnosis of Epstein-Barr virus infection, such as infectious mononucleosis",
    "fda_folder": "Microbiology"
}